



UNIVERSITY OF LEEDS

This is a repository copy of *Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer*.

White Rose Research Online URL for this paper:
<http://eprints.whiterose.ac.uk/109312/>

Version: Supplemental Material

Article:

Bell, R, Brown, JM orcid.org/0000-0002-2719-7064, Parmar, M et al. (18 more authors) (2017) Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer. *Annals of Oncology*, 28 (4). pp. 754-760. ISSN 0923-7534

<https://doi.org/10.1093/annonc/mdw665>

© The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. This is a pre-copyedited, author-produced PDF of an article accepted for publication in *Annals of Oncology* following peer review. The version of record, 'Bell, R, Brown, JM, Parmar, M et al (2017) Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer. *Annals of Oncology*, 28 (4). pp. 754-760,' doi: 10.1093/annonc/mdw665; is available online at: <https://doi.org/10.1093/annonc/mdw665>.

Reuse

Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher's website.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

Supplementary Table S1. Baseline characteristics and planned adjuvant chemotherapy choice (ITT population)

Characteristic	Chemotherapy alone (N = 1290)	Chemotherapy + bevacizumab (N = 1301)
Age, years, N (%)		
<40	253 (19.6)	231 (17.8)
40–64	916 (71.0)	952 (73.2)
≥65	121 (9.4)	118 (9.1)
Menopausal status, N (%)		
Premenopausal	665 (51.6)	676 (52.0)
Postmenopausal	625 (48.4)	625 (48.0)
ECOG performance status, N (%)		
0	1186 (91.9)	1202 (92.4)
1	94 (7.3)	98 (7.5)
2	1 (<0.1)	0
Missing	9 (0.7)	1 (<0.1)

Geographic region, N (%)

USA, Australia, Western	792 (61.4)	783 (60.2)
Europe		
Eastern Europe, Greece, Israel	160 (12.4)	148 (11.4)
South and Central America	37 (2.9)	22 (1.7)
Asia, New Zealand	301 (23.3)	348 (26.7)

Race, N (%)

White	968 (75.0)	932 (71.6)
Asian	280 (21.7)	333 (25.6)
Black	32 (2.5)	29 (2.2)
Other	10 (0.8)	7 (0.5)

Tumor size, cm (tumor stage),
N (%)

>0–<2 (T1)	457 (35.4)	482 (37.0)
2–<5 (T2)	759 (58.8)	755 (58.0)
≥5 (T3)	71 (5.5)	61 (4.7)
Missing	3 (0.2)	3 (0.2)

AJCC stage I, N (%)	388 (30.1)	382 (29.4)
Hormone receptor status ^a , N (%)		
ER and PgR negative	1224 (94.9)	1229 (94.5)
ER and/or PgR low	66 (5.1)	72 (5.5)
Positive axillary nodes ^a , N (%)		
0	814 (63.1)	824 (63.3)
1–3	326 (25.3)	322 (24.8)
≥4	150 (11.6)	155 (11.9)
Ductal/invasive histology, N (%)	1183 (91.7)	1209 (92.9)
Grade 3 tumor, N (%)	895 (69.4)	912 (70.1)
Type of surgery ^a , N (%)		
Breast conserving	817 (63.3)	827 (63.6)
Mastectomy	473 (36.7)	474 (36.4)
Planned adjuvant chemotherapy ^a , N (%)		
Anthracycline	468 (36.3)	479 (36.8)

Anthracycline and taxane	756 (58.6)	752 (57.8)
Taxane	66 (5.1)	70 (5.4)
Hormonal therapy, N (%)	7 (0.5)	4 (0.3)
Radiotherapy, N (%)	953 (73.9)	952 (73.2)

^aStratification factor (data as recorded in interactive voice-response system).

AJCC, American Joint Committee on Cancer; ECOG, Eastern Cooperative Oncology Group; ER, estrogen receptor; ITT, intent to treat; PgR, progesterone receptor.
